Sector News

WuXi AppTec to acquire US-based clinical research services firm

May 10, 2019
Energy & Chemical Value Chain

WuXi AppTec has announced that has acquired Pharmapace (San Diego, California), a clinical research services company with expertise in providing biometrics services for all phases of clinical trials, regulatory submissions, and post marketing support. Pharmapace will become a wholly owned subsidiary of WuXi Clinical and will continue to focus on growing its core biometrics competences and integrate with WuXi Clinical’s other clinical development services.

Pharmapace, which was founded in 2013, provides a full range of biometrics services for all phases of clinical trials, including clinical and statistical programming, data management, biostatistics, clinical data integration, and medical writing. The acquisition enables WuXi Clinical to expand its biometrics capabilities in the US and Europe. By integrating Pharmapace and WuXi Clinical biometrics teams, WuXi Clinical will be able to provide its customers with efficient and cost-effective biometrics services, the company says.

“This acquisition further enhances WuXi Clinical’s drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost-effectively provide customers seamless biometrics services,” says Edward Hu, co-CEO, WuXi AppTec. “Together, we [will be] able to shorten time-to-market of new drugs and to achieve the dream that ‘every drug can be made and every disease can be treated’,” Hu says.

By Michael Ravenscroft

Source: Chemical Week

comments closed

Related News

February 25, 2024

Antwerp Declaration for a European Industrial Deal: industry leaders call for 10 urgent actions to restore competitiveness and keep good jobs in Europe

Energy & Chemical Value Chain

During a European Industry Summit held on the site of BASF in Antwerp, leaders from basic industry sectors, representing 7.8 million workers in Europe, joined forces with European trade unions and European leaders to address pressing concerns regarding Europe’s industrial landscape.

February 25, 2024

Blue hydrogen could contribute 50% more to global warming than fossil fuels

Energy & Chemical Value Chain

The use of blue or low-carbon hydrogen, made from natural gas with carbon capture and storage (CCS), could increase near-term global warming by 50% compared with burning fossil fuels directly for energy if emissions are not properly managed, according to a new study by NGO the US Environmental Defense Fund (EDF) and the University of Arizona.

February 25, 2024

EU approves €6.9 Billion state aid for 33 hydrogen projects

Energy & Chemical Value Chain

In a move to improve the supply of renewable hydrogen and thus reduce dependence on natural gas and contribute to achieving the objectives of the European Green Deal and the REPowerEU plan, the EU Commission has approved a third Important project of common European interest (IPCEI) to support hydrogen infrastructure.

How can we help you?

We're easy to reach